Stockreport

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology [Yahoo! Finance]

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagon [Read more]